Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
703 (USA) · Dr. Okafor
consented 2013-03-16
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild DECREASED APPETITE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-04 (study day 50.0); relationship: POSSIBLE
moderate
assessed
Moderate DECREASED APPETITE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-04 (study day 50.0); relationship: POSSIBLE
mild
assessed
Mild DISORIENTATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-02 (study day 18.0); relationship: REMOTE
Data queries
No data queries.